Key facts
- Vesteck’s last known valuation is $1.9M (Oct 2025).
- It has raised $26.1M across 2 recorded rounds; the latest was Seed Round ($2.3M) in Dec 2022.
- Notable investors include Ben Franklin Technology Partners of Southeastern Pennsylvania, Robin Hood Ventures, BioAdvance Capital (Conshohocken), The Entrust Group, Angel Star Ventures — 11 tracked in total.
- Vesteck has filed 2 Form Ds with the SEC since 2021, most recently Jan 2023 ($2.3M sold to 30 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Vesteck
Funding rounds
2 roundsAbout Vesteck
Developer of medical devices designed to treat patients diagnosed with aortic disease. The company offers devices that suture endovascular grafts to the aorta during implant or repair procedures, virtually eliminating graft migration and leaks, enabling endovascular providers, payors, and patients to gain greater procedural stability and long-term therapeutic benefit.
- Sector
- Healthcare
- HQ
- West Chester, PA, United States
- Founded
- 2019
- Employees
- 5
- Website
- vesteck.com/
- Ownership
- Privately Held (backing)
Vesteck doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vesteck shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vesteck in its N-PORT filings yet. We sweep new filings monthly.